CN104974988B - 抗胰腺癌单克隆抗体及其应用 - Google Patents
抗胰腺癌单克隆抗体及其应用 Download PDFInfo
- Publication number
- CN104974988B CN104974988B CN201510466976.2A CN201510466976A CN104974988B CN 104974988 B CN104974988 B CN 104974988B CN 201510466976 A CN201510466976 A CN 201510466976A CN 104974988 B CN104974988 B CN 104974988B
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- pancreas
- cancer
- application
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 82
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 79
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 42
- 201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 20
- 230000002946 anti-pancreatic effect Effects 0.000 title abstract description 5
- 239000000427 antigen Substances 0.000 claims abstract description 54
- 102000036639 antigens Human genes 0.000 claims abstract description 54
- 108091007433 antigens Proteins 0.000 claims abstract description 54
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 21
- 210000000496 pancreas Anatomy 0.000 claims abstract description 20
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 7
- 230000028327 secretion Effects 0.000 claims abstract description 3
- 238000003745 diagnosis Methods 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 238000004393 prognosis Methods 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 3
- 238000013399 early diagnosis Methods 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000013115 immunohistochemical detection Methods 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 42
- 210000004027 cell Anatomy 0.000 abstract description 37
- 201000010099 disease Diseases 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 229920001817 Agar Polymers 0.000 abstract description 12
- 239000008272 agar Substances 0.000 abstract description 12
- 230000004069 differentiation Effects 0.000 abstract description 7
- 230000012010 growth Effects 0.000 abstract description 7
- 238000011580 nude mouse model Methods 0.000 abstract description 7
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 abstract description 6
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 description 25
- 238000000034 method Methods 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 238000007689 inspection Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 238000011470 radical surgery Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241001269238 Data Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010061000 Benign pancreatic neoplasm Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100029801 Calcium-transporting ATPase type 2C member 1 Human genes 0.000 description 1
- 108050001979 Calcium-transporting ATPase type 2C member 1 Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 1
- DUKURNFHYQXCJG-JEOLMMCMSA-N alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000012482 calibration solution Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 208000012106 cystic neoplasm Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940005654 nitrite ion Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000005221 pancreatic serous cystadenoma Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/067—Pancreatitis or colitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510466976.2A CN104974988B (zh) | 2015-07-31 | 2015-07-31 | 抗胰腺癌单克隆抗体及其应用 |
US15/749,490 US10444237B2 (en) | 2015-07-31 | 2016-07-26 | Anti-pancreatic cancer monoclonal antibody and use thereof |
PCT/CN2016/091737 WO2017020752A1 (zh) | 2015-07-31 | 2016-07-26 | 抗胰腺癌单克隆抗体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510466976.2A CN104974988B (zh) | 2015-07-31 | 2015-07-31 | 抗胰腺癌单克隆抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104974988A CN104974988A (zh) | 2015-10-14 |
CN104974988B true CN104974988B (zh) | 2016-08-24 |
Family
ID=54271952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510466976.2A Active CN104974988B (zh) | 2015-07-31 | 2015-07-31 | 抗胰腺癌单克隆抗体及其应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US10444237B2 (zh) |
CN (1) | CN104974988B (zh) |
WO (1) | WO2017020752A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104974988B (zh) * | 2015-07-31 | 2016-08-24 | 南京麦科林生物医药科技有限公司 | 抗胰腺癌单克隆抗体及其应用 |
CN112300283B (zh) * | 2019-07-29 | 2024-01-02 | 深圳华大生命科学研究院 | 一种抗人胰腺癌单克隆抗体及其制备方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060258841A1 (en) * | 2003-01-17 | 2006-11-16 | Josef Michl | Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods |
US20080131428A1 (en) * | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
AU2011207189B2 (en) * | 2008-08-08 | 2014-01-16 | Immunomedics, Inc. | Detection of early-stage pancreatic adenocarcinoma |
CN102137681B (zh) * | 2008-08-08 | 2014-12-03 | 埃姆诺医药有限公司 | 抗胰腺癌抗体 |
CN102321173B (zh) * | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
CN104974988B (zh) * | 2015-07-31 | 2016-08-24 | 南京麦科林生物医药科技有限公司 | 抗胰腺癌单克隆抗体及其应用 |
-
2015
- 2015-07-31 CN CN201510466976.2A patent/CN104974988B/zh active Active
-
2016
- 2016-07-26 WO PCT/CN2016/091737 patent/WO2017020752A1/zh active Application Filing
- 2016-07-26 US US15/749,490 patent/US10444237B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20180224457A1 (en) | 2018-08-09 |
CN104974988A (zh) | 2015-10-14 |
US10444237B2 (en) | 2019-10-15 |
WO2017020752A1 (zh) | 2017-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6240112B2 (ja) | 腫瘍細胞由来微小胞 | |
CN101570575B (zh) | Sncg的单克隆抗体及其应用 | |
CN101519649B (zh) | 杂交瘤细胞株及其制备方法 | |
CN104974988B (zh) | 抗胰腺癌单克隆抗体及其应用 | |
CN102507943B (zh) | 一种用于检测非小细胞肺癌的双抗体夹心elisa试剂盒及其制备方法 | |
CN103923212A (zh) | Ehd2抗体及其在制备乳腺癌免疫组化检测试剂中的应用 | |
CN109468380A (zh) | Il1r2在乳腺癌预后评估与靶向治疗中的应用 | |
KR102429562B1 (ko) | 간세포암 진단용 바이오마커 세레브론 및 이에 특이적인 신규한 단일클론항체 | |
JP5145549B2 (ja) | 腫瘍マーカー | |
CN105353132B (zh) | non B‑s IgG作为干/祖细胞标志物的应用 | |
CN103555668B (zh) | 杂交瘤细胞株及其产生的抗Wnt5a单克隆抗体与应用 | |
CN109709328A (zh) | 一种卵巢癌的诊断标志物及其应用 | |
CN105753960B (zh) | 一种肿瘤标志物及其应用 | |
Zhang et al. | Identification and characterization of monoclonal antibodies against GP73 for use as a potential biomarker in liver cancer screening and diagnosis | |
CN111996251B (zh) | 一种恶性胶质瘤生物标志物的应用 | |
KR102129532B1 (ko) | Pten 억제제에 대한 췌장암 치료 반응성 예측용 바이오마커 및 이의 용도 | |
CN105462935B (zh) | 抗卵巢癌单克隆抗体及其应用 | |
CN104945496A (zh) | 一种多肽及其在制备与纯化对ehd2特异的抗体中的应用 | |
CN104945506A (zh) | 一种用于乳腺癌诊断和预后判断的免疫组化试剂 | |
CN102297971A (zh) | 一种检测癌或恶性肿瘤组织中jwa表达的试剂盒 | |
Chao et al. | Downregulation of LHPP Expression Associated with AFP Acts as a Good Prognostic Factor in Human Hepatocellular Carcinoma | |
Wei et al. | Establishment of a monoclonal antibody against a peptide of the novel zinc finger protein ZNF32 proved to be specific and sensitive for immunological measurements | |
Liu et al. | Talin1 promotes HCC progression by regulating NRG1/PI3K/AKT axis | |
CN103103263A (zh) | 利用高通量组织芯片检测golph3在脑胶质瘤中的表达的方法 | |
Guan et al. | CCL5 promotes the epithelial-mesenchymal transition of circulating tumor cells in renal cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20151014 Assignee: JIANGSU KEDE BIO-MEDICINE TECHNOLOGY CO.,LTD. Assignor: Nanjing Renchen Biotechnology Co.,Ltd. Contract record no.: 2015320000650 Denomination of invention: Anti-pancreatic cancer monoclonal antibody and application thereof License type: Common License Record date: 20151218 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160727 Address after: Spark Road 210032 Jiangsu province Nanjing city high tech Development Zone No. 10 Dingye biotech building block D Room 308 Applicant after: NANJING MARKERLINE BIOMEDICAL TECHNOLOGY Co.,Ltd. Address before: 210032, Jiangsu Province, Pukou District, Nanjing hi tech Development Zone, 10 Spark Road, ding industry, 100 Thai biological building, block D, room 306 Applicant before: Nanjing Renchen Biotechnology Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20151014 Assignee: JIANGSU KEDE BIO-MEDICINE TECHNOLOGY CO.,LTD. Assignor: NANJING MARKERLINE BIOMEDICAL TECHNOLOGY Co.,Ltd. Contract record no.: 2017320000069 Denomination of invention: Anti-pancreatic cancer monoclonal antibody and application thereof Granted publication date: 20160824 License type: Common License Record date: 20170310 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180403 Address after: 210032 room No. 307, block D, No. 10, Batai bio building, No. 10, Xing fire road, Jiangbei new area, Jiangsu Patentee after: JIANGSU KEDE BIO-MEDICINE TECHNOLOGY CO.,LTD. Address before: Spark Road 210032 Jiangsu province Nanjing city high tech Development Zone No. 10 Dingye biotech building block D Room 308 Patentee before: NANJING MARKERLINE BIOMEDICAL TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230310 Address after: Room 308, Block D, Dingye Baitai Biological Building, No. 10 Xinghuo Road, Nanjing High-tech Zone, Jiangsu Province Patentee after: NANJING MARKERLINE BIOMEDICAL TECHNOLOGY Co.,Ltd. Address before: Room 307, Block D, Dingye Baitai Biological Building, No. 10 Xinghuo Road, Jiangbei New District, Nanjing City, Jiangsu Province Patentee before: JIANGSU KEDE BIO-MEDICINE TECHNOLOGY CO.,LTD. |